EnglishLapatinib is an oral, small-molecule dual inhibitor of human EGF receptor 1 (EGFR/erbB1) and 2 (HER2/erbB2). Lapatinib has recently been approved, in combination with capecitabine, for the treatment of HER2-positive metastatic breast cancer patients failing trastuzumab therapy. Data from clinical trials are consistently showing the key role of this agent in the management of HER2-positive disease. Moreover, interesting data are suggesting a key role of lapatinib in enhancing endocrine responsiveness and/or restoring endocrine sensitivity in hormone receptor-positive disease. The present article will summarize the main data leading to the clinical development of the combination of lapatinib and the aromatase inhibitor letrozole
Lapatinib plus letrozole for postmenopausal patients with advancedHER2(+)/HR(+) breast cancer / Guarneri, Valentina. - In: EXPERT REVIEW OF ANTICANCER THERAPY. - ISSN 1473-7140. - ELETTRONICO. - 9(2009), pp. 1549-1557.
| Data di pubblicazione: | 2009 |
| Titolo: | Lapatinib plus letrozole for postmenopausal patients with advancedHER2(+)/HR(+) breast cancer. |
| Autore/i: | Guarneri, Valentina |
| Autore/i UNIMORE: | |
| Rivista: | |
| Volume: | 9 |
| Pagina iniziale: | 1549 |
| Pagina finale: | 1557 |
| Codice identificativo Scopus: | 2-s2.0-71949087792 |
| Codice identificativo Pubmed: | 19895239 |
| Citazione: | Lapatinib plus letrozole for postmenopausal patients with advancedHER2(+)/HR(+) breast cancer / Guarneri, Valentina. - In: EXPERT REVIEW OF ANTICANCER THERAPY. - ISSN 1473-7140. - ELETTRONICO. - 9(2009), pp. 1549-1557. |
| Tipologia | Articolo su rivista |
File in questo prodotto:
http://hdl.handle.net/11380/640742
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
Copyright © 2021